Navigation Links
New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
Date:8/8/2012

IPSWICH, Mass., Aug. 8, 2012 /PRNewswire/ -- New England Biolabs (NEB) has released a novel DNA polymerase, Q5 High-Fidelity DNA Polymerase, that provides the highest fidelity amplification currently available, while also offering robust amplification across the broadest range of amplicons, including those that are GC- and AT-rich.

(Photo:  http://photos.prnewswire.com/prnh/20120808/NE54308 )

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

High fidelity amplification is essential for experiments whose outcome depends upon the correct DNA sequence, such as sequencing, SNP detection, protein expression and gene function studies. However, results from such amplifications can be compromised by a DNA polymerase incapable of evenly amplifying diverse types of sequences. For example, high-fidelity PCR of GC-rich regions and other challenging amplicons can lead to lower yields and even non-specific amplification. In addition, any bias in library amplification, associated with next generation sequencing, can lead to challenges in sequence assembly and even "missing" sequence, a problem of growing concern in the sequencing community.

NEB's novel polymerase is fused to the processivity-enhancing Sso7d DNA binding domain, which improves fidelity (more than 50-fold higher than Taq), speed, and performance reliability (amplifying targets up to 20 kb long with extension times as low as 10 seconds per kb). The Q5 buffer system has also been extensively optimized to provide robust performance across both high-GC and high-AT regions, as well as other challenging amplicons.

"High-fidelity polymerases have tended to be more susceptible to difficulties in the PCR amplification of GC-rich or other challenging amplicons. Q5 polymerase has dramatically reduced these limitations and raised the bar for high-fidelity DNA amplification," says Fiona Stewart, Ph.D., Product Marketing Manager at NEB.

A hot start version of the Q5 polymerase, which utilizes a synthetic aptamer for room-temperature set up, is also available. Both the Q5 and Q5 Hot Start DNA Polymerases are available as standalone enzymes or in 2X master mix format for added convenience. A separate formulation has also been developed specifically to meet the needs of amplification of next generation sequencing libraries (NEBNext® High-Fidelity 2X PCR Master Mix).

The discovery and development of high-fidelity polymerases has been, for many years, a key focus of NEB's research. Beginning with the discovery of Vent® DNA Polymerase from Thermococcus litoralis in 1990, and more recently the commercialization of Phusion® DNA Polymerase, NEB researchers have identified and developed a number of high-fidelity polymerases with differing processivities, speeds and degrees of accuracy. Q5 DNA Polymerase is the most recent and highest-performing enzyme to have been added to this list. For more information and supporting data on Q5 DNA Polymerase, visit www.Q5PCR.com.

About New England Biolabs


Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and six subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com


Phusion DNA Polymerase was developed by Finnzymes Oy, now a part of Thermo Fisher Scientific.
PHUSION® is a registered trademark and property of Thermo Fisher Scientific.
NEBNEXT® and VENTR® are registered trademarks of New England Biolabs.
Q5 is a trademark of New England Biolabs.


'/>"/>
SOURCE New England Biolabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
2. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
3. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
4. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
5. UCLA-led research team develops worlds most powerful nanoscale microwave oscillators
6. Medi-Solve Coatings Develops Masking Process for Medical Devices
7. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
8. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
9. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
10. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
11. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 Regen BioPharma, ... RGBPP) announced today initiation of a preclinical development ... based cancer immunotherapeutic product leveraging its NR2F6 immunological ... a generation of cord blood derived killer cells ...  The product in development will be a "universal ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific Instruments ... University of Toledo. This two-day camp will take place annually starting June 2016. ... of pharmaceutical sciences in preparation for a university academic program. , The ...
(Date:5/18/2016)... (PRWEB) , ... May 18, 2016 , ... ... 1,200 hospitalizations are a direct result of asthma complications.* Costing more than $56 ... the country. , “For too many, the suffering associated with ...
(Date:5/17/2016)... 2016 Haselmeier announces the launch ... approval by EMA, the European Medicines Agency. Originally launched ... company, the new pen version includes enhancements to further ... confidence to patients during use. Its enhanced ... to handle with a larger display window that improves ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):